$RLFTF / $NRXP reply: From Nrx website
Oct 11, 2021
NRx
$RLFTF / $NRXP reply: From Nrx website
Oct 11, 2021
NRx is pleased to announce that last week a revised Investigational New Drug module on the manufacturing of ZYESAMI™ (aviptadil) was submitted to the US Food and Drug Administration (FDA), containing documentation that confirmed Nephron Pharmaceuticals, Inc. is prepared to supply ZYESAMI on a commercial scale. This module will now be used as part of the FDA’s rolling review process in support of the New Drug Application for ZYESAMI.
Today, NRx also received notification that a European Qualified Person Auditor (European QP) has completed an inspection at a separate manufacturing facility with no adverse findings and awaits a QP Declaration that is required by the EU regulatory authorities for release of ZYESAMI. The audit was completed in preparation for submission of European Union (EU)-standard ZYESAMI to EU and United Kingdom health regulatory authorities. Under EU law, a QP Auditor is responsible for certifying that each batch of a medicinal product meets all required provisions when released from a manufacturing facility within the EU or imported into the EU.
Finally, NRx notes that Relief Therapeutics Holdings issued a press release advising of a complaint filed in the Supreme Court of the State of New York against NeuroRx. The Company vigorously disputes the allegations made in the press release and intends to defend its position in court. These events do not in any manner affect our efforts to bring a lifesaving drug to patients worldwide.
Additional information will be provided to shareholders in an 8K filing that will be published once the US Securities and Exchange Commission reopens the filing system after the Columbus Day and Indigenous People’s Day holidays.
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...
Continue Reading
Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...
Continue Reading
Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...
Continue Reading
Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...
Continue Reading
The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...
Continue Reading
Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...
Continue Reading
Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...
Continue Reading
Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...
Continue Reading
Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...
Continue Reading
Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...
Continue Reading
Top 5 Most Recently Viewed Articles
Legal Rights for Shareholders of Paragon 28, Inc. Attention shareholders of Paragon 28, Inc. (NYSE: FNA): As developments unfold regarding potential legal action related to financial misconduct, it is crucial for you to understand your rights and options. If you purchased shares of FNA during the specified class period, there are steps you can take to ensure that your...
Continue Reading
Embecta Corp. Financial Results Conference Call Embecta Corp. (“embecta”) (Nasdaq: EMBC), a prominent global player in diabetes care, is gearing up to present its financial performance for the fiscal second quarter of 2025. This pivotal event will offer stakeholders a comprehensive look at the company's recent achievements and ongoing operational updates. Conference...
Continue Reading
Investigation of HealthEquity, Inc. Pomerantz LLP is currently investigating claims on behalf of investors from HealthEquity, Inc. (NASDAQ: HQY). Investors who believe they may have been impacted are encouraged to reach out for further information. This investigation focuses on whether HealthEquity and certain officers or directors have been involved in securities fraud...
Continue Reading
Health-E Commerce Teams Up with Sesame for Better Care The new collaboration significantly shortens waiting periods for those seeking mental health and dermatology consultations, delivering substantial savings for millions enrolled in tax-advantaged FSAs and HSAs. Accessible Mental Health and Dermatology Solutions Health-E Commerce, the parent organization behind FSA...
Continue Reading
Hyperliquid's Promising Future in the Crypto Market As the cryptocurrency landscape continues to evolve, analysts are closely observing the potential of various altcoins. Recently, a well-known crypto analyst, Sherpa, has highlighted the altcoin Hyperliquid, predicting an exciting journey ahead for its utility token, HYPE. Analyst’s Predictions for Hyperliquid Expected...
Continue Reading